Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia

S. Ji; A. Li; K. Wu; C. Deng; F. Dong; L. Li; T. Zhou; W. Yue; C.-Y. Wang; W. Lu

doi:10.1055/s-0035-1569360

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2016; 49(03): 117-123
DOI: 10.1055/s-0035-1569360

Original Paper

Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia

S. Ji^#

¹State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China

⁴School of Pharmaceutical Sciences, Peking University, Beijing, China

,

A. Li^#

²Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China

³Beijing Anding Hospital, Capital Medical University, Beijing, China

,

K. Wu

¹State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China

⁴School of Pharmaceutical Sciences, Peking University, Beijing, China

,

C. Deng

⁵Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

,

F. Dong

²Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China

³Beijing Anding Hospital, Capital Medical University, Beijing, China

,

L. Li

¹State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China

⁴School of Pharmaceutical Sciences, Peking University, Beijing, China

,

T. Zhou

¹State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China

⁴School of Pharmaceutical Sciences, Peking University, Beijing, China

,

W. Yue

⁶Institute of Mental Health, The Sixth Hospital, Peking University, Beijing, China

,

C.-Y. Wang^*

²Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China

³Beijing Anding Hospital, Capital Medical University, Beijing, China

,

W. Lu^*

¹State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China

²Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China

⁴School of Pharmaceutical Sciences, Peking University, Beijing, China

› Author Affiliations

Abstract

Aim: Patients with schizophrenia require continuous treatment much longer than the duration of their hospitalization, which makes their family members essential in their medical care. However, the evaluation of the disease state could only be done by professionals. This prompted us to seek potent indicators of disease states that are understandable and easy to use for the patients’ family.

Method: Specific items were firstly extracted from the total PANSS scale. Then 3 096 PANSS scores were analyzed using a nonlinear mixed-effects model (NONMEM). A questionnaire was subsequently developed for family members to assess and monitor the overall severity of schizophrenia. Finally this questionnaire was validated in 33 patients.

Results: 2 items (P1 and N4) were extracted from the 8 effective remission items according to the correlation coefficients between the total PANSS score and different combinations of items. P1N4 was defined as the sum of these 2 items. A model was then developed to describe the probability of PANSS≥60, with P1N4 as indicators. The results indicated that P1N4 could make a good predictor of the overall probability of PANSS≥60, which was independent of treatment. A brief questionnaire with 7 questions was developed based on the results. External validation results indicated the questionnaire’s suitability for a good assessment.

Conclusion: Questionnaire developed based on P1 and N4 may facilitate the patients’ family members to better understand the disease state and help to prevent relapse.

Key words

schizophrenia - nonlinear mixed-effects modeling (NONMEM) - probability model

Full Text

References

References
1 Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335: 91-95
2 Salkever DS, Karakus MC, Slade EP et al. Measures and predictors of community-based employment and earnings of persons with schizophrenia in a multisite study. Psychiatr Serv 2007; 58: 315-324
3 Bond GR, Drake RE. Predictors of competitive employment among patients with schizophrenia. Curr Opin Psychiatry 2008; 21: 362-369
4 Van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645
5 Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24: 81-90
6 Newman JM, Turnbull A, Berman BA et al. Impact of traumatic and violent victimization experiences in individuals with schizophrenia and schizoaffective disorder. J Nerv Ment Dis 2010; 198: 708-714
7 Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
8 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
9 Zhang YS, Si TM, Li KQ. A survey of antipsychotic usage in treatment of schizophrenia in China 2006. Chinese Mental Health Journal 2012; 26: 736-740
10 Schizophrenia. http://www.mentalhealth.com/home/dx/schizophrenia_advanced.html
11 Magliano L, Fiorillo A, De Rosa C et al. The National Mental Health Project Working Group. Family burden in long-term diseases: A comparative study in schizophrenia vs. physical disorders. Soc Sci Med 2005; 61: 313-322
12 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
13 Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization. Br J Psychiatry Suppl 1989; 7: 59-67
14 Lindenmayer JP, Harvey PD, Khan A et al. Schizophrenia: measurements of psychopathology. Psychiatr Clin North Am 2007; 30: 339-363
15 Opler MG, Yang LH, Caleo S et al. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007; 7: 35
16 Li WS, Zhao Y, Fang W. The effect of group psychotherapy on improving the symptoms of middle-aged or youth schizophrenia patients. China Journal of Health Psychology 2014; 22: 331-333
17 Zhang CG, Wei BY, Zhang R. Clinical observation of aripiprazole in the treatment of schizophrenia. J Clin Psychosom Dis 2005; 11: 223-224
18 Leucht S, Kane JM, Kissling W et al. What does the PANSS mean?. Schizophr Res 2005; 79: 231-238
19 Jenkins JH, Carpenter-Song E. The new paradigm of recovery from schizophrenia: cultural conundrums of improvement without cure. Cult Med Psychiatry 2005; 29: 379-413
20 Caqueo-Urizar A, Rus-Calafell M, Urzua A et al. The role of family therapy in the management of schizophrenia: challenges and solutions. Neuropsychiatr Dis Treat 2015; 11: 145-151
21 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
22 Montgomery SA, Taylor P, Montgomery D. Development of a schizophrenia scale sensitive to change. Neuropharmacology 1978; 17: 1061-1063
23 Seo JM, Byun EK, Park KY et al. Development of a coping scale for families of patients with schizophrenia. Journal of Korean Academy of Nursing 2012; 42: 738-748
24 Yamamoto N, Inada T, Shimodera S et al. Brief PANSS to assess and monitor the overall severity of schizophrenia. Psychiatry Clin Neurosci 2010; 64: 262-267
25 Andreasen NC, Carpenter Jr WT, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449
26 Chan HY, Lin AS, Chen KP et al. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. J Clin Psychopharmacol 2013; 33: 747-752
27 Canuso CM, Schooler N, Carothers J et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010; 30: 487-495
28 Takahashi N, Takahashi M, Saito T et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat 2013; 8: 1889-1898
29 Yue WH, Wang HF, Sun LD et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nature Genetics 2011; 43: 1228-1231
30 Wang W, Chen QS, Liu ZM. To calculate and evaluate the ICC using Excel. Chin J Hlt Stat 2008; 25: 314-315
31 Yu HM, Luo YH, Sa J et al. To calculate ICC using different software. Chin J Hlt Stat 2011; 28: 497-499